Based on the Relmada Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Relmada Therapeutics Inc is USD 7.50 over the next 12 months. Relmada Therapeutics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Relmada Therapeutics Inc is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Relmada Therapeutics Inc’s stock price was USD 3.16. Relmada Therapeutics Inc’s stock price has changed by -3.07% over the past week, -5.67% over the past month and +7.12% over the last year.
No recent analyst target price found for Relmada Therapeutics Inc
No recent average analyst rating found for Relmada Therapeutics Inc
Company Overview Relmada Therapeutics Inc
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. Read Less
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone,...Read More
Frequently Asked Questions About Relmada Therapeutics Inc (RLMD) Stock
Based on ratings from 2 analysts Relmada Therapeutics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on RLMD's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for RLMD is USD 7.50 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 2.
RLMD stock's Price/Earning ratio is -99,999.99.
Our analysis grades RLMD stock's Price / Earning ratio at A+. This means that RLMD stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RLMD may be undervalued for its sector.
The last closing price of RLMD's stock was USD 3.16.
The most recent market capitalization for RLMD is USD 0.11B.
Based on targets from 2 analysts, the average taret price for RLMD is projected at USD 7.50 over the next 12 months.
This means that RLMD's stock price may go up by +137.34% over the next 12 months.
We can't find any ETFs which contains Relmada Therapeutics Inc's stock.
As per our most recent records Relmada Therapeutics Inc has 20 Employees.
Relmada Therapeutics Inc's registered address is 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134.
You can get more information about it from Relmada Therapeutics Inc's website at https://www.relmada.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Relmada Therapeutics Inc (RLMD) Stock
Based on ratings from 2 analysts Relmada Therapeutics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on RLMD's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for RLMD is USD 7.50 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 2.
RLMD stock's Price/Earning ratio is -99,999.99.
Our analysis grades RLMD stock's Price / Earning ratio at A+. This means that RLMD stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RLMD may be undervalued for its sector.
The last closing price of RLMD's stock was USD 3.16.
The most recent market capitalization for RLMD is USD 0.11B.
Based on targets from 2 analysts, the average taret price for RLMD is projected at USD 7.50 over the next 12 months.
This means that RLMD's stock price may go up by +137.34% over the next 12 months.
We can't find any ETFs which contains Relmada Therapeutics Inc's stock.
As per our most recent records Relmada Therapeutics Inc has 20 Employees.
Relmada Therapeutics Inc's registered address is 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134.
You can get more information about it from Relmada Therapeutics Inc's website at https://www.relmada.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RLMD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
